Dr Sue Chua
- Consultant Radiologist and Nuclear Medicine Physician
- Clinical Lead for Nuclear Medicine and PET/CT
- Nuclear Medicine and PET/CT Research Lead
- BSc
- MBBS
- MRCPCH
- FRCR
Biography
Dr Sue Chua is a Multimodality Imaging Consultant with dual accreditation in radiology and nuclear medicine. She graduated in Sydney, Australia, in 1997 and undertook radiology training in Nottingham (2001–05) and nuclear medicine and PET/CT training (2005-07) in Nottingham, the Institute of Nuclear Medicine at UCLH, and the Oklahoma Heart Hospital, USA.
Dr Chua was appointed to The Royal Marsden in 2008 with a remit to support and develop PET/CT research activity. She is research lead for PET/CT at The Royal Marsden with responsibility for all phase I and II studies. Her research interests are principally in multimodality functional imaging, in particular PET/CT and functional CT and MRI imaging, which have an increasingly important role in detecting changes in tumours at the cellular and molecular level in order to offer improved outcome prediction and treatment efficacy assessment in cancer management. Her clinical and research areas of interest include lymphoma, upper and lower GI, lung, paediatric oncology, soft-tissue tumours and neuro-oncology
She is actively involved in many prospective trials and retrospective trials (selected trials are listed below), in both single and multi-centre settings, locally, nationally and internationally. She is a member of the PET/CT expert panel for the NCRI PET Research Network and the NCRI Brain (Clinical Trials Unit) CSG Imaging Subgroup. Locally, at The Royal Marsden and The Institute of Cancer Research, she is PET/CT trial advisor for the Phase 1 Drug Development Unit.
Open trials
- Pre-treatment Staging and Post-treatment Assessment in Malignant Lymphoma by Whole Body Diffusion-weighted MR Imaging (WB-DWI) and ADC-mapping in comparison to 18F-FDG PET/CT
- A Multicenter Trial to Evaluate 18F-FDG Uptake by PET in Patients with Advanced Pancreatic Adenocarcinoma as an Early Indicator of Drug Activity
- A Phase II, open-label test-retest study to assess the reproducibility of quantitative measurements of 18F uptake by solid tumours using PET imaging following intravenous administration of AH111585 (18F) injection
- A phase II study of Sunitinib and low dose metronomic cyclophosphamide in advanced renal cell cancer; a single centre CT perfusion and 18F-FDG PET/CT imaging substudy
- A Phase 1 Open-Label, Dose-Finding Study to Evaluate the Safety and Pharmacokinetics of ONX 0801, a Novel alpha-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Advanced Solid Tumors – Multicentre 18F-FLT PET/CT imaging substudy
- Timing of Rectal Surgery Following a Continued Incremental Response to Pre-operative Chemoradiotherapy – “Deferral of Surgery” – Multicentre 18F-FDG PET/CT imaging lead
- Is greater downstaging and tumour regression observed when surgery is delayed to 12 weeks after completion of CRT vs 6 weeks – 18F-FDG PET/CT imaging lead
Education and training
Dr Chua is an educational supervisor on the nuclear medicine specialist registrar training scheme and teaches regularly on nuclear medicine MSc courses.
Clinical teams